Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Aberrant vascular network is a hallmark of cancer. However, the role of vascular endothelial
cells (VECs)-expressing PD-L1 in tumor immune microenvironment and antiangiogenic …

Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …